End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
52 CNY | -1.83% | -5.64% | -16.17% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 68.42 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.17% | 965M | - | ||
-15.52% | 19.69B | A | ||
-39.00% | 3.01B | C+ | ||
+22.02% | 1.94B | - | ||
-0.62% | 1.66B | - | ||
+35.83% | 1.34B | B+ | ||
-22.01% | 895M | - | C- | |
+6.26% | 827M | - | ||
-23.80% | 638M | B+ | ||
+10.38% | 516M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688212 Stock
- Ratings Shanghai AoHua Photoelectricity Endoscope Co., Ltd.